Drug Profile
Research programme: ubiquitin modulators - Progenra
Alternative Names: Cbl-b inhibitors - Progenra; Deubiquitylating enzyme inhibitors - Progenra; MuRF1 inhibitors - Progenra; P 013222; P 022077; P 13222; P 5091; P005091; P1001; P1002; P1003; Synoviolin/Hrd1 inhibitors - Progenra; ubiquitin isopeptidase inhibitors - Progenra; USP2 inhibitors - Progenra; USP47 inhibitors - Progenra; USP7 inhibitors - ProgenraLatest Information Update: 04 Dec 2023
Price :
$50
*
At a glance
- Originator Progenra
- Class Anti-inflammatories; Antiasthmatics; Antineoplastics; Antipsoriatics; Small molecules
- Mechanism of Action CBLB protein expression inhibitors; Endopeptidase inhibitors; Ubiquitin-protein ligase inhibitors; USP2 protein inhibitors; USP47 protein inhibitors; USP7 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Asthma; Cancer; Psoriasis
- No development reported Multiple myeloma; Muscular atrophy; Rheumatoid arthritis
Most Recent Events
- 28 Nov 2023 Preclinical trials in Asthma in USA (unspecified route) (Progenra website; November 2023)
- 28 Nov 2023 Preclinical trials in Psoriasis in USA (unspecified route) (Progenra website; November 2023)
- 28 Nov 2023 Preclinical development is ongoing in Cancer in USA (Progenra website; November 2023)